











Prior Authorization Request Administrative Information

| Member Information | | | | | |
|---|--------------------|--------------------------|------|--|--|
| Last name | First name | | МІ | | |
| Member ID | Date of birth | | | | |
| | X" or Intersex | | | | |
| Current gender Female Male Transge | ender male 🔲 Tra | nsgender female Othe | - | | |
| Place of residence Home Nursing facility | Other | | | | |
| Race/ethnicity Preferred spoken la | anguage | Preferred written lang | uage | | |
| MassHealth does not exclude people or treat them differently because of race, color, national origin, age, disability, religion, creed, sexual orientation, or sex (including gender identity and gender stereotyping). | | | | | |
| Plan Contact Information | | | | | |
| Please indicate the member's MassHealth Plan according to the Plan's contact information belo | | his completed and signed | form | | |
| MassHealth Fee-For-Service (FFS) Plan, Primary Care Clinician (PCC) Plan, Primary Care Accountable Care Organization (PCACO) Plan, Children's Medical Security Plan, and Health Safety Net Plan | | | | | |
| ☐ MassHealth Drug Utilization Review Program | | | | | |
| Pharmacy: Fax: (877) 208-7428 - Tel: (800 |) 745-7318 | | | | |
| MassHealth Managed Care Organization (MCO) and Accountable Care Partnership Plans (ACPP) | | | | | |
| ☐ Fallon Health | | | | | |
| Online Prior Authorization: go.covermymeds.com/OptumRx | | | | | |
| Online Prior Authorization: providerportal.surescripts.net/ProviderPortal/optum | | | | | |
| Pharmacy: Fax: (844) 403-1029 - Tel: (844) 720-0033 | | | | | |
| ☐ Health New England | | | | | |
| Online Prior Authorization: go.covermymeds.com/OptumRx | | | | | |
| Pharmacy: Fax: (800) 550-9246 - Tel: (800) 918-7545 | | | | | |
| | | | | | |
| Online Prior Authorization (Non-Specialty Drugs): go.covermymeds.com/OptumRx | | | | | |
| Online Prior Authorization (Specialty/Medical Drugs): provider.massgeneralbrighamhealthplan.org | | | | | |
| Pharmacy: Fax: (844) 403-1029 - Tel: (800) 711-4555 | | | | | |
| ☐ Tufts Health Plan | | | | | |
| Online Prior Authorization: point32health.promptpa.com | | | | | |
| Pharmacy: Fax: (617) 673-0939 - Tel: (888) 257-1985 | | | | | |
| ☐ WellSense Health Plan | | | | | |
| Online Prior Authorization: wellsense.org/p | roviders/ma/pharma | acy/prior-authorizations | | | |
| Pharmacy: Fax: (833) 951-1680 - Tel: (877) 417-1822 | | | | | |

Breast Cancer Agents Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at **www.mass.gov/druglist**.

| Medication information | | | | | | |
|--|---|--|--|--|--|--|
| Medication requested | | | | | | |
| ☐ Enhertu (fam-trastuzumab deruxtecan-nxki) ™ | ☐ Kisqali-Femara Co-Pack (ribociclib/letrozole) | | | | | |
| ☐ everolimus 2.5 mg, 5 mg, 7.5 mg, 10 mg | ☐ Margenza (margetuximab-cmkb) ^{MB} | | | | | |
| everolimus tablets for oral suspension | ☐ Nerlynx (neratinib) | | | | | |
| ☐ fulvestrant MB | ☐ Ogivri (trastuzumab-dkst) ^{MB} | | | | | |
| ☐ Halaven (eribulin) ^{MB} | ☐ Ontruzant (trastuzumab-dttb) ^{MB} | | | | | |
| ☐ Herceptin (trastuzumab) ^{MB} | Perjeta (pertuzumab) MB | | | | | |
| ☐ Herceptin Hylecta (trastuzumab-hyaluronidase- oysk) ^{MB} | ☐ Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) ^{MB} | | | | | |
| ☐ Herzuma (trastuzumab-pkrb) ^{MB} | ☐ Piqray (alpelisib) | | | | | |
| ☐ Ibrance (palbociclib) | ☐ Trazimera (trastuzumab-qyyp) ^{MB} | | | | | |
| ☐ Kadcyla (ado-trastuzumab) ^{MB} | ☐ Trodelvy (sacituzumab govitecan-hziy) ^{MB} | | | | | |
| ☐ Kanjinti (trastuzumab-anns) ^{MB} | ☐ Tukysa (tucatinib) | | | | | |
| ☐ Kisqali (ribociclib) | ☐ Verzenio (abemaciclib) | | | | | |
| listed, prior authorization does not apply through the h 130 CMR 433.408 for prior authorization requirements above, this drug may be an exception to the unified ph | r this drug to be dispensed through the retail pharmacy. If ospital outpatient and inpatient settings. Please refer to for other health care professionals. Notwithstanding the narmacy policy; please refer to respective MassHealth maged Care Organizations (MCOs) for prior authorization | | | | | |
| Dose, frequency, and duration of medication requested | | | | | | |
| Height Weight | Date | | | | | |
| Please indicate prescriber specialty below. | | | | | | |
| ☐ Oncology ☐ Other | | | | | | |
| Will the requested agent be used as monotherapy for If no, please list all other medications currently pre this indication. | this indication? Yes No scribed for the member that will be used concomitantly for | | | | | |
| | | | | | | |

PA-82 (Rev. 04/24) over

| If yes, please descr Please indicate billing p | nt be used as adjuvant or neo ibe. Adjuvant Neoadju preference. Pharmacy so complete section for profes | uvant Prescriber in-office Hos | pital outpatient |
|---|--|--|--|
| Drug NDC (if known) o | service code | • | |
| ☐ Breast cancer ☐ Early ☐ Ad Other Oncologic In ☐ Liposarcoma ☐ Locally advance ☐ Metastatic gastr ☐ Metastatic non-s | nat apply or include ICD-10 contact apply or include ICD-10 contact apply or include ICD-10 contact apply and include ICD-10 contact apply | ecurrent Unresectable ncer on (GEJ) adenocarcinoma C) with activating HER2 (ER | BB2) mutations |
| Please describe pertine ER-positive ER-negative | ent mutations if applicable. HER2-positive HER2-negative HER2-low | ☐ HR-positive ☐ HR-negative | RAS wild-type Triple negative |
| Has the member had p | • | | diation therapy? |
| ☐ Yes ☐ No. Please | late for surgery and/or radiat | ion? | |
| Please list any other pr Drug name Did the member ex | | Dates/duration of use | ee and outcomes below.* adequate response Other |
| | | | adequate response Other |
| Drug name Did the member ex | | Dates/duration of use | |

| * Please attach a letter documenting additional trials as necessary. | | |
|---|--|--|
| II. Please complete for requests for agents with a preferred alternative. describe clinical rationale for use of the requested agent instead of the preferred alternative. | | |
| | | |
| | | |
| | | |
| III. Please complete for requests for quantities above quantity limits. describe the clinical rationale for exceeding the quantity limit, including a detailed treatment plan. | | |
| | | |
| IV. Please include any other pertinent information (if needed). | | |
| | | |
| | | |
| V. Please complete and provide documentation for exceptions to Step Therapy. e alternative drug required under the step therapy protocol contraindicated, or will likely cause an adverse tion in, or physical or mental harm to the member? Yes No yes, briefly describe details of contraindication, adverse reaction, or harm. | | |
| e alternative drug required under the step therapy protocol expected to be ineffective based on the known cal characteristics of the alternative drug regimen? es \[\] No yes, briefly describe details of known clinical characteristics of member and alternative drug regimen. | | |
| the member previously tried the alternative drug required under the step therapy protocol, or another native drug in the same pharmacologic class or with the same mechanism of action, and such alternative was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event? es \(\subsetential \) No yes, please provide details for the previous trial. | | |
| | | |

| 1. | Is the member stable on the requested prescription drug prescribed by the health care provider, and switching drugs will likely cause an adverse reaction in or physical or mental harm to the member? |
|----|--|
| | ☐ Yes. Please provide details. ☐ No |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | Please continue to next page and complete Prescriber and Provider Information section. |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

Prior Authorization Request Prescriber and Provider Information

| Prescriber Information | | |
|---|---|--|
| Last name* | First name* | MI |
| NPI* | Individual MH Provide | er ID |
| DEA No. | Office Contact Name | |
| Address | City | State Zip |
| Email address | | |
| Telephone No.* | Fax No.* | |
| * Required | | |
| Please also complete for professionally | administered medication | ns, if applicable. |
| Start date | End date | |
| Servicing prescriber/facility name | | ☐ Same as prescribing provider |
| Servicing provider/facility address | | |
| Servicing provider NPI/tax ID No. | | |
| Name of billing provider | | |
| Billing provider NPI No. | | |
| Is this a request for recertification? Yes |] No | |
| CPT code No. of visits | J code | No. of units |
| Prescribing provider's attestation, signal certify under the pains and penalties of perjoinformation section of this form. Any attached I certify that the medical necessity information complete, to the best of my knowledge. I under prosecution for any falsification, omission, or | ury that I am the prescribing I statement on my letterhead (per 130 CMR 450.204) on erstand that I may be subject concealment of any material | has been reviewed and signed by me. this form is true, accurate, and to civil penalties or criminal I fact contained herein. |
| Prescribing provider's signature | | _ |
| Printed name of prescribing provider (The form can either be signed by hand and | | |

(The form can either be signed by hand and then scanned, or it can be signed electronically using DocuSign or Adobe Sign. For electronic signatures, the signer can upload a picture of their wet signature. The typed text of a signature is not an acceptable form of an electronic signature.)